Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Actinogen Medical ( (AU:ACW) ).
Actinogen Medical has reached a significant milestone in its XanaMIA phase 2b/3 clinical trial for Alzheimer’s disease, enrolling over 100 participants and planning an interim analysis in January 2026. Additionally, the company has secured a $13.8 million R&D tax incentive funding facility and completed a scale-up batch of Xanamem tablets, positioning itself for potential commercialization and partnerships.
More about Actinogen Medical
Actinogen Medical is a biotechnology company focused on developing innovative treatments for neurological conditions, particularly Alzheimer’s disease. The company is engaged in clinical trials and research to advance its primary product, Xanamem, which targets elevated blood biomarkers associated with Alzheimer’s.
Average Trading Volume: 7,733,709
Technical Sentiment Signal: Sell
Current Market Cap: A$79.43M
Find detailed analytics on ACW stock on TipRanks’ Stock Analysis page.